Literature DB >> 16281287

An interactive web database of factor H-associated hemolytic uremic syndrome mutations: insights into the structural consequences of disease-associated mutations.

Rebecca E Saunders1, Timothy H J Goodship, Peter F Zipfel, Stephen J Perkins.   

Abstract

Factor H (FH) is a central complement regulator comprised of 20 short complement repeat (SCR) domains. Nucleotide changes within this gene (CFH) have been observed in patients with hemolytic uremic syndrome (HUS), and also membranoproliferative glomerulonephritis and age-related macular degeneration. All parts of FH are affected, but many mutations are clustered in the C-terminal part of FH. Up to now, structural analyses of HUS have been based on SCR-20, a domain that is involved in FH interactions with C3b, heparin, and endothelial cells. In order to identify the structural and functional consequence of HUS mutations, further disease-associated mutations were analyzed in terms of homology and nuclear magnetic resonance (NMR) models for factor H SCR domains. An interactive web database of 54 human HUS-associated mutations and others was created from the literature (www.FH-HUS.org). This has comprehensive search and analysis tools, integrating phenotypic and genetic data with structural analysis. Each mutation can be highlighted on the SCR structure together with the patient FH and C3 levels where available. Two new insights were obtained from our collection of data. First, phenotypic data on FH clarify our previously-proposed classification of Type I and Type II disorders that both lead to HUS, where Type I affects FH secretion and folding, and Type II leads to expressed protein in plasma that is functionally defective. Second, the new mutations show more clearly that SCR domains from SCR-16 to SCR-19 are important for the ligand binding activities of FH as well as SCR-20. This FH web database will facilitate the interpretation of new mutations and polymorphisms when these are identified in patients, and it will clarify the functional role of FH. 2005 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16281287     DOI: 10.1002/humu.20268

Source DB:  PubMed          Journal:  Hum Mutat        ISSN: 1059-7794            Impact factor:   4.878


  27 in total

1.  Membrano-proliferative glomerulonephritis, atypical hemolytic uremic syndrome, and a new complement factor H mutation: report of a case.

Authors:  Elisa Gnappi; Marco Allinovi; Augusto Vaglio; Elena Bresin; Annalisa Sorosina; Francesco P Pilato; Landino Allegri; Lucio Manenti
Journal:  Pediatr Nephrol       Date:  2012-06-05       Impact factor: 3.714

2.  Autoantibodies to CD59, CD55, CD46 or CD35 are not associated with atypical haemolytic uraemic syndrome (aHUS).

Authors:  Rachael Watson; Emma Wearmouth; Amy-Claire McLoughlin; Arthur Jackson; Sophie Ward; Paula Bertram; Karim Bennaceur; Catriona E Barker; Isabel Y Pappworth; David Kavanagh; Susan M Lea; John P Atkinson; Timothy H J Goodship; Kevin J Marchbank
Journal:  Mol Immunol       Date:  2014-08-21       Impact factor: 4.407

3.  Heparan sulfate, including that in Bruch's membrane, inhibits the complement alternative pathway: implications for age-related macular degeneration.

Authors:  Una Kelly; Ling Yu; Pallavi Kumar; Jin-Dong Ding; Haixiang Jiang; Gregory S Hageman; Vadim Y Arshavsky; Michael M Frank; Michael A Hauser; Catherine Bowes Rickman
Journal:  J Immunol       Date:  2010-09-27       Impact factor: 5.422

Review 4.  What's new in haemolytic uraemic syndrome?

Authors:  Sally Johnson; C Mark Taylor
Journal:  Eur J Pediatr       Date:  2008-06-25       Impact factor: 3.183

5.  Guideline for the investigation and initial therapy of diarrhea-negative hemolytic uremic syndrome.

Authors:  Gema Ariceta; Nesrin Besbas; Sally Johnson; Diana Karpman; Daniel Landau; Christoph Licht; Chantal Loirat; Carmine Pecoraro; C Mark Taylor; Nicole Van de Kar; Johan Vandewalle; Lothar B Zimmerhackl
Journal:  Pediatr Nephrol       Date:  2008-09-18       Impact factor: 3.714

6.  Determination of complement factor H functional polymorphisms (V62I, Y402H, and E936D) using sequence-specific primer PCR and restriction fragment length polymorphisms.

Authors:  Adrienn Bíró; Zoltán Prohászka; George Füst; Bernadett Blaskó
Journal:  Mol Diagn Ther       Date:  2006       Impact factor: 4.074

7.  Individuals homozygous for the age-related macular degeneration risk-conferring variant of complement factor H have elevated levels of CRP in the choroid.

Authors:  P T Johnson; K E Betts; M J Radeke; G S Hageman; D H Anderson; L V Johnson
Journal:  Proc Natl Acad Sci U S A       Date:  2006-11-01       Impact factor: 11.205

Review 8.  aHUS caused by complement dysregulation: new therapies on the horizon.

Authors:  Aoife M Waters; Christoph Licht
Journal:  Pediatr Nephrol       Date:  2010-06-18       Impact factor: 3.714

9.  Dissection of functional sites in herpesvirus saimiri complement control protein homolog.

Authors:  Malik Johid Reza; Ashish Kamble; Muzammil Ahmad; Musti V Krishnasastry; Arvind Sahu
Journal:  J Virol       Date:  2012-10-17       Impact factor: 5.103

10.  Structure of complement fragment C3b-factor H and implications for host protection by complement regulators.

Authors:  Jin Wu; You-Qiang Wu; Daniel Ricklin; Bert J C Janssen; John D Lambris; Piet Gros
Journal:  Nat Immunol       Date:  2009-06-07       Impact factor: 25.606

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.